Posted by Michael Wonder on 05 Sep 2023
Aquipta (atogepant) receives MHRA marketing authorisation for the prevention of migraines in adults
4 September 2023 - The marketing authorisation is based on results from two pivotal Phase 3 studies in which the treatment demonstrated significant reduction in mean monthly migraine days from baseline across 12 weeks.
AbbVie today announced that the MHRA has granted a marketing authorisation for Aqiupta (atogepant) for the prophylaxis of migraine in adults who have at least four migraine days per month.
